Stay updated on RGN-259 Ophthalmic Solutions for Dry Eye Syndrome Clinical Trial
Sign up to get notified when there's something new on the RGN-259 Ophthalmic Solutions for Dry Eye Syndrome Clinical Trial page.

Latest updates to the RGN-259 Ophthalmic Solutions for Dry Eye Syndrome Clinical Trial page
- ChecktodayChange DetectedThe site’s footer revision label was updated from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe study record for the Phase 3 ARISE-3 dry-eye trial is displayed, including its design, eligibility criteria, locations, outcome measures, and posted study documents and results.SummaryDifference66%

- Check21 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0. The page continues to show a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check28 days agoChange DetectedA sitewide banner announces NIH website updates and says NIH content may use “Super Intelligence” alongside “Artificial Intelligence” during the transition.SummaryDifference1%

- Check35 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check42 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

Stay in the know with updates to RGN-259 Ophthalmic Solutions for Dry Eye Syndrome Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RGN-259 Ophthalmic Solutions for Dry Eye Syndrome Clinical Trial page.